enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. ResMed - Wikipedia

   en.wikipedia.org/wiki/ResMed

   ResMed Inc. is an American medical equipment company based in San Diego, California.It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

3. It's Showtime for ResMed - AOL

   www.aol.com/2012/10/25/its-showtime-for-resmed

   ResMed (NYS: RMD) is expected to report Q1 earnings on Oct. 25. Here's what Wall Street wants to see: The 10-second takeaway Comparing the upcoming quarter to the prior-year quarter, average ...

4. Holiday sleep trouble? 5 secrets of a better snooze

   www.aol.com/holiday-sleep-trouble-5-secrets...

   Dr. Brian Licuanan, a board-certified clinical psychologist in California, offers expert advice for ensuring good quality sleep over the holidays, which can pose challenges.

5. From 'worst president' to 'highest respect': Trump softens ...

   www.aol.com/worst-president-highest-respect...

   Donald Trump mocked Jimmy Carter as worst president in history. But after Carter's death, Trump suggested ex-leader had his 'highest respect.'

6. The Reasons that Induced Dr. S. to Write a Poem Call'd the ...

   en.wikipedia.org/wiki/The_Reasons_that_Induced_Dr...

   The poem's biting satire obviously overtly attacks Dr. Swift and his writings. It also actively accuses Swift of misogyny and sexism. Swift's poem was highly invasive as it chronicles the unwanted entry of a man into a lady's dressing room where he sees the woman no longer as an elevated goddess, but as a normal human being with normal bodily functions.

7. GLP-1 Diet Plan: What It Is & How to Get Started - AOL

   www.aol.com/glp-1-diet-plan-started-125800192.html

   GLP-1 Diet Plan. GLP-1 medications — that’s glucagon-like peptide-1 receptor agonists — are prescribed alongside diet and exercise to help people lose weight or manage type 2 diabetes. But ...